Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction

Clinical Biochemistry

Volumn 39, Issue 8, 2006, Pages 771-780

  Yang, Zhen ^a   Min Zhou, Dao ^b  

^a SHENZHEN UNIVERSITY   (China)

^b University of Southern California ^*  (United States)

Author keywords

Acute myocardial infarction (AMI); Cardiac markers; Central laboratory testing (CLT); Point of care testing (POCT)

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CREATINE KINASE MB; D DIMER; MYELOPEROXIDASE; MYOGLOBIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ATHEROGENESIS; ATHEROSCLEROSIS; BIOASSAY; BLOOD FLOW; CARDIAC PATIENT; CARDIOVASCULAR SYSTEM EXAMINATION; CELL DEATH; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; LABORATORY TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL INFARCTION; POINT-OF-CARE SYSTEMS;

EID: 33746878456     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.05.011     Document Type: Review

References (101)

1. Thom T., Hasse N., Rosamond W., Howard V.J., et al. Heart disease and stroke statistics-2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Wu A.H.B., Apple F.S., Gibler W.B., Jesse R.L., Warshaw M.M., and Valdes R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. 45 (1999) 1104-1121
3. Pope J.H., Aufderheide T.P., Ruthazer R., et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med. 342 (2000) 1163-1170
4. Drenck N.-E. Point of care testing in critical care medicine: the clinician's view. Clin. Chim. Acta. 307 (2001) 3-7
5. Azzazy H.M.E., and Christenson R.H. Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing?. Clin. Biochem. 35 (2002) 13-27
6. Shebuski R.J. Utility of point-of-care diagnostic testing in patients with chest pain and suspected acute myocardial infarction. Curr. Opin. Pharmacol. 2 (2002) 160-164
7. Hudson M.P., Christenson R.H., Newby K., Kaplan A.L., and Ohman E.M. Cardiac markers: point of care testing. Clin. Chim. Acta. 284 (1999) 223-237
8. Apple F.S., Wu A.H.B., Mair J., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 51 (2005) 810-824
9. Wu A.H.B. Markers for early detection of cardiac diseases. Scand. J. Clin. Lab. Invest. 65 Suppl. 240 (2005) 112-121
10. Bernard R., Corday E., Eliasch H., et al. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 59 (1979) 607-609
11. Yusuf S., Pearson M., Sterry H., et al. The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur. Heart J. 5 (1984) 690-696
12. Mizuno K., Satomura K., Miyamoto A., et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N. Engl. J. Med. 326 (1992) 287-291
13. Lee T.H., Weisberg M.C., Brand D.A., Rouan G.W., and Goldman L. Candidates for thrombolysis among emergency room patients with acute chest pain: potential true and false positive rates. Ann. Intern. Med. 110 (1989) 957-962
14. Alpert J.S., Thygesen K., Antman E., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 36 (2000) 959-969
15. Ohman E.M., Armstrong P.W., White H.D., et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. Am. J. Cardiol. 84 (1999) 1281-1286
16. Panteghini M. The new definition of myocardial infarction and the impact of troponin determination on clinical practice. Int. J. Cardiol. 106 (2006) 298-306
17. Wong C.-K., and White H.D. Implications of the new definition of myocardial infarction. Postgrad. Med. J. 81 (2005) 552-555
18. Kontos M.C., Fritz L.M., Anderson F.P., Tatum J.L., Ornato J.P., and Jesse R.L. Impact of the troponin standard on the prevalence of acute myocardial infarction. Am. Heart J. 146 (2003) 446-452
19. Zahger D, Hod H, Gottlieb S, et al. Influence of the new definition of acute myocardial infarction on coronary care unit admission, discharge diagnosis, management and outcome in patients with non-ST elevation acute coronary syndromes: a national survey. Int J Cardiol 2006;106:164-9.
20. Brogan Jr. G.X., Friedman S., McCuskey C., et al. Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. Ann. Emerg. Med. 24 (1994) 665-671
21. Storrow A.B., and Gibler W.B. The role of cardiac markers in the emergency department. Clin. Chim. Acta. 284 (1999) 187-196
22. Christenson R.H., and Azzazy H.M.E. Biochemical markers of the acute coronary syndromes. Clin. Chem. 44 (1998) 1855-1864
23. Males R.G., Stephenson J., and Harris P. Cardiac markers and point-of-care testing: the perfect fit. Crit. Care Nurs. Q. 24 (2001) 54-61
24. Panteghini M. Diagnostic applications of CK-MB mass determination. Clin. Chim. Acta. 272 (1998) 23-31
25. Young G.P., Hedges J.R., Gibler W.B., Green T.R., and Swanson R. Does CK-MB affect chest pain decision making in the emergency department?. Ann. Emerg. Med. 20 (1991) 1220-1228
26. Hedges J.R., Glbler W.B., Young G.P., et al. Multicenter study of creatine kinase-MB use: effect on chest pain and clinical decision making. Acad. Emerg. Med. 3 (1996) 7-15
27. Hoekstra J.W., Hedges J.R., Gibler W.B., Rubison R.M., and Christensen R.A. Emergency department CK-MB: a predictor of ischemic complications. Acad. Emerg. Med. 1 (1994) 17-28
28. Galla J.M., Mahaffey K.W., Sapp S.K., et al. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am. Heart J. 151 (2006) 16-24
29. Katus H.A., Remppis A., Looser S., Hallermeyer K., Scheffold T., and Kubler W. Enzyme linked immunoassay of cardiac troponin T for the detection of acute myocardial infarction in patients. J. Mol. Cell. Cardiol. 21 (1989) 1349-1353
30. Bodor G.S., Porter S., Landt S., and Ladenson J.H. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin. Chem. 38 (1992) 2203-2214
31. Babuin L., and Jaffe A.S. Troponin: the biomarker of choice for the detection of myocardial injury. Can. Med. Assoc. J. 173 (2005) 1191-1202
32. Martins J.T., Li D.J., Baskin L.B., Jialal I., and Keffer J.H. Comparison of cardiac troponin I and lactate dehydrogenase isoenzymes for the late diagnosis of myocardial injury. Am. J. Clin. Pathol. 106 (1996) 705-708
33. Licka M., Zimmermann R., Zehelein J., et al. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 87 (2002) 520-524
34. Panteghini M., Cuccia C., Bonetti G., et al. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin. Chem. 48 (2002) 1432-1436
35. Newby L.K., Goldmann B.U., and Ohman E.M. Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol. 41 (2003) 31S-36S [Suppl. S]
36. Heeschen C., van den Brand M.J., Hamm C.W., et al. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 100 (1999) 1509-1514
37. Jeremias A., and Gibson C.M. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann. Intern. Med. 142 (2005) 786-791
38. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur. Heart J. 25 (2004) 1187-1196
39. Melanson S.F., and Tanasijevic M.J. Laboratory diagnosis of acute myocardial injury. Cardiovasc. Pathol. 14 (2005) 156-161
40. Nicholson J.K., Foxall P.J., Spraul M., et al. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal. Chem. 67 (1995) 793-811
41. Mo V.Y., and De Lemos J.A. Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. Curr. Cardiol. Rep. 6 (2004) 273-278
42. Fichtlscherer S., Heeschen C., and Zeiher A.M. Inflammatory markers and coronary artery disease. Curr. Opin. Pharmacol. 4 (2004) 124-131
43. De Ferranti S., and Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin. Chim. Acta. 317 (2002) 1-15
44. Yeh E.T.H. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin. Cardiol. 28 (2005) 408-412
45. Brennan M.L., Penn M.S., van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349 (2003) 1595-1604
46. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
47. Heeschen C., Dimmeler S., Fichtlscherer S., et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291 (2004) 435-441
48. Lenderink T., Heeschen C., Fichtlscherer S., et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 47 (2006) 307-311
49. Lin T.M., Galbert S.P., Kiefer D., et al. Characterization of four human pregnancy-associated plasma proteins. Am. J. Obstet. Gynecol. 118 (1974) 223-236
50. Bayes-Genis A., Conover C.A., Overgaard M.T., et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med. 345 (2001) 1022-1029
51. Heeschen C., Dimmeler S., Hamm C.W., et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes. Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45 (2005) 229-237
52. Hayashida K., Kume N., Murase T., et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 112 (2005) 778-780
53. Sajurai S., Inoue A., Koh C.-S., Owa M., and Yanagisawa N. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc. Med. 2 (1997) 163-168
54. Hollander J.E., Muttreja R., Dalesandro M.R., and Shofer F.S. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J. Am. Coll. Cardiol. 33 (1999) 95-105
55. Hollander JE, Muttreja MR, Dalesandro MR, Shofer FS. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol 1999;34:95-105.
56. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348 (2003) 1104-1111
57. Ridker P.M., Hennekens C.H., Cerskus A., and Stampfer M.J. Plasma concentration of cross-linked fibrin degradation product (d-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90 (1994) 2236-2240
58. Bayes-Genis A., Mateo J., Santalo M., et al. d-dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am. Heart J. 140 (2000) 351-353
59. Moresco R.N., Vargas L.C.R., Halla R., and Silla L.M.R. Lack of association between cardiac troponin T and d-dimer in the evaluation of myocardial damage. J. Clin. Lab. Anal. 19 (2005) 282-284
60. Glatz J.F.C., van der Voort D., and Hermens W.T. Fatty acid-binding protein as the earliest available plasma marker of acute myocardial injury. J. Clin. Ligand. Assay. 25 (2002) 167-177
61. Pelsers M.M.A.L., Hermens W.T., and Glatz J.F.C. Fatty acid-binding proteins as plasma markers of tissue injury. Clin. Chim. Acta. 352 (2005) 15-35
62. Chan C.P., Sanderson J.E., Glatz J.F., Cheng W.S., Hempel A., and Renneberg R. A superior early myocardial infarction marker-human heart-type fatty acid-binding protein. Z. Kardiol. 93 (2004) 388-397
63. Sinha M.K., Roy D., Gaze D.C., Collinson P.O., and Kaski J.C. Role of "ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg. Med. J. 21 (2004) 29-34
64. Bar-Or D., Lau E., and Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med. 19 (2000) 311-315
65. Christenson R.H., Duh S.H., Sanhal W.R., et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin. Chem. 47 (2001) 464-470
66. Anwaruddin S., Januzzi Jr. J.L., Baggish A.L., Lewandrowski E.L., and Lewandrowski K.B. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am. J. Clin. Pathol. 123 (2005) 140-145
67. Roy D., Quiles J., Aldama G., et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int. J. Cardiol. 97 (2004) 297-301
68. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J. Am. Coll. Cardiol. 38 (2001) 2101-2113
69. Remme W.J., and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22 (2001) 1527-1560
70. De Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345 (2001) 1014-1021
71. Jernberg T., James S., Lindahl B., Stridsberg M., Venge P., and Wallentin L. NT-proBNP in unstable coronary artery disease-experiences from the FAST, GUSTO IV and FRISC II trials. The. Eur. J. Heart Fail. 6 (2004) 319-325
72. Pfister P., and Schneider C.A. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?. Clin. Chim. Acta. 349 (2004) 25-38
73. Penney M.D.I. Natriuretic peptides and the heart: current and future implications for clinical biochemistry. Ann. Clin. Biochem. 42 (2005) 432-440
74. Kleinfeld A.M., Kleinfeld K.J., and Adams III J.E. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J. Am. Coll. Cardiol. 39 Suppl. 2 (2002) 312
75. Danne O., Möckel M., Lueders C., et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am. J. Cardiol. 91 (2003) 1060-1067
76. Chaava M., Bukia T., and Gogokhia N. Significance of homocysteines in the development of acute myocardial infarction. Georgian Med. News 121 (2005) 64-67
77. Altekin E., Coker C., Sisman A.R., Onvural B., Kuralay F., and Kirimli O. The relationship between trace elements and cardiac markers in acute coronary syndromes. J. Trace Elem. Med. Biol. 18 (2005) 235-242
78. Gibler W.B., Lewis L.M., Erb R.E., et al. Early detection of acute myocardial infarction in patients presenting with chest pain and nondiagnostic electrocardiograms: serial CK-MB sampling in the emergency department. Ann. Emerg. Med. 19 (1990) 1359-1366
79. Newby L.K., Storrow A.B., and Gibler W.B. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 103 (2001) 1832-1837
80. Serebruany V.L., Levine D.J., Nair G.V., Meister A.F., and Gurbel P.A. Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the Emergency Department. J. Thromb. Thrombolysis 11 (2001) 155-162
81. Von Lode P. Point-of-care immunotesting: approaching the analytical performance of central laboratory methods. Clin. Biochem. 38 (2005) 591-606
82. Apple F.S., Murakami M.M., Christenson R.H., et al. Analytical performance of the i-STAT cardiac troponin assay. Clin. Chim. Acta. 345 (2004) 123-127
83. Wu A.H.B., Smith A., Christenson R.H., Murakami M.M., and Apple F.S. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin. Chim. Acta. 346 (2004) 211-219
84. Rogic D., Radic M., Fressl G., and Fucek M. Evaluation of RAMP troponin I point of care assay. Point of care: the journal of near-patient testing and technology 4 (2005) 24-26
85. Ahn J.S., Choi S., Jang S.H., et al. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. Clin. Chim. Acta. 332 (2003) 51-59
86. Di Serio F., Antonelli G., Trerotoli P., Tampoia M., Matarrese A., and Pansini N. Appropriateness of point-of-care testing (POCT) in an emergency department. Clin. Chim. Acta. 333 (2003) 185-189
87. Goldmann B.U., Langenbrink L., Matschuck G., et al. Quantitative bedside testing of troponin T: is it equal to laboratory testing? The Cardiac Reader Troponin T (CARE T) study. Clin. Lab. 50 (2004) 1-10
88. Chapelle J.-P., Aldenhoff M.-C., Pierard L., and Gielen J. Comparison of cardiac troponin I measurements on whole blood and plasma on the Stratus CS analyzer and comparison with AxSYM. Clin. Chem. 46 (2000) 1864-1866
89. Storrow AB, Apple FS, Wu AHB, Jesse R, Francis G, Christenson RH. NACB: Laboratory guidelines for evidence-based practice for POCT-2004 (draft guidelines). Point-of-care testing: recommendations for utilization of cardiac biomarkers of acute coronary syndromes. Available at http://www.nacb.org/lmpg/poct/chp3_cardiac.pdf.
90. McCord J., Nowak R.M., McCullough P.A., et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 104 (2001) 1483-1488
91. Collinson P.O., John C., Cramp D.R.G., and Canepa-Anson R. Prospective randomized controlled trial of point of care testing with central laboratory testing for cardiac enzyme measurement. Clin. Chem. 44 (1998) A69 [suppl]
92. Singer A.J., Ardise J., Gulla J., and Cangro J. Point-of-care testing reduces length of stay in emergency department chest pain patients. Ann. Emerg. Med. 45 (2005) 587-591
93. Mutrie D.A. New chest pain strategy in Thunder Bay. Can. J. Emerg. Med. 1 (1999) 57-60
94. Fraser C.G. Optimal analytical performance for point of care testing. Clin. Chim. Acta. 307 (2001) 37-43
95. Panteghini M., and Pagani F. Biological variation of myoglobin in serum. Clin. Chem. 43 (1997) 2435
96. Ross S.M., and Fraser C.G. Biological variation of cardiac markers: analytical and clinical considerations. Ann. Clin. Biochem. 35 (1998) 80-84
97. Panteghini M., Pagani F., Yeo K.-T.J., et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin. Chem. 50 (2004) 327-332
98. Apple F.S. Clinical and analytical standardization issues confronting cardiac troponin I. Clin. Chem. 45 (1999) 18-20
99. Katrukha A.G., Bereznikova A.V., Filatov V.L., et al. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin. Chem. 44 (1998) 2433-2440
100. Collinson P.O., Boa F.G., and Gaze D.C. Measurement of cardiac troponins. Ann. Clin. Biochem. 38 (2001) 423-449
101. Wu A.H.B., Feng Y.J., Moore R., et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I· American Association for Clinical Chemistry Subcommittee on cTnI standardization. Clin. Chem. 44 (1998) 1198-1208